Biological Evidences of Hepatocellular Carcinoma Treatment with 1,3,4-oxadiazole-2-thiol as Anticancer Agent
- *Corresponding Author:
- Shimaa S Abdelhady
National Organization for Drug Control and Research (NODCAR)
12553, Giza, Egypt
E-mail: [email protected]
Received Date: June 07, 2017; Accepted Date: June 12, 2017; Published Date: June 22, 2017
Citation: Gabry MS, Elgemeie GH, Basseli NS, Melek ST, Hafez SE, et al. (2017) Biological Evidences of Hepatocellular Carcinoma Treatment with 1,3,4-oxadiazole-2- thiol as Anticancer Agent. J Biomol Res Ther 6:153. doi: 10.4172/2167-7956.1000153
Copyright: © 2017 Gabry MS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Purpose: In recent years, identification of novel potent, selective, and less toxic anticancer agents remains one of the most pressing health problems. This research aimed to in vivo illustration of 1,3,4-oxadiazole-2-thiol (OXD-T) anticancer activities as a discovery of the treatment of Hepatocellular Carcinoma (HCC) of Albino rats.
Methods: Hepatocellular carcinoma was induced by 3,3’-Diamino benzidine for three months, three times per week. The post treatment of HCC induced rats was carried out with OXD-T therapeutic (300 mg/kg. b.wt.) and half therapeutic doses (150 mg/kg b.wt.) of administration. Biochemical parameters and comet assay were assessed to evaluate the efficiency of OXD-T treatment on the HCC induced animal.
Results: The administration of 1,3,4-oxadiazole-2-thiol (OXD-T) with therapeutic dose and half therapeutic dose to hepatocellular carcinoma (HCC) induced rats affected the biochemical values as biomarkers; prothrombin induced by vitamin K absence-II (PIVKA-II) and lactate dehydrogenase LDH. Also, serum enzymes; AST, ALT, GGT and Albumin. Furthermore, OXD-T affected the DNA fragmentation parameters (tail length, tail moment, % DNA in tail and % DNA in head of comet). OXD-T therapeutic administration revealed highly significant decreases in the biochemical values and DNA fragmentation parameters more than half dose of OXD-T treatment.
Conclusion: OXD-T antimetabolite with different therapeutic doses of administration affected the growth of hepatocellular carcinoma.